Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q1 2026 Earnings Presentation
14 slides from Angiodynamics's earnings presentation, Oct 2, 2025
Slide 1: First Quarter FY 2026 Earnings Results
First Quarter FY 2026 Earnings Results October 2, 2025
Slide 2: Forward looking statements
Forward looking statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: FY Q1 2026 Key Takeaways
FY Q1 2026 Key Takeaways Continued commercial and operational execution positions AngioDynamics to drive accelerated, profitable growth moving forward. Continued Commercial Execution – Fiscal Q1 FY 2026 YoY Revenue Total Med Tech Med Device Growth* +12.2% +26.1% +2.3% Med Tech YoY Auryon Mech Thromb
Slide 4: Demonstrated Med Tech Growth Execution
Demonstrated Med Tech Growth Execution Pro Forma Fiscal Year Net Sales ($M) $308 - $313 $293 $271 $257 $235 +14% - 16% Med Tech $206 $106 $127 ~47% of Total Med Tech $186 $79 $96 $56 ~22% of Total $41 $150 $156 $161 $165 $166 $145 FY20 A FY21 A FY22 A FY23 A FY24 A FY25 A FY26 G* Med Device Med Tech
Slide 5: Q1 FY 2026 Financial Snapshot
Q1 FY 2026 Financial Snapshot Net Sales Segment Revenue Contribution Q1 25 Q1 26 $75.7 $67.5 +26.1% 41% 47% Pro Forma Growth 53% $35.3 59% $28.0 Med Device Med Tech Med Device Med Tech +2.3% Segment Gross Margin Pro Forma Growth $39.5 $40.4 49.3% 62.2% Q1 25 Q1 26 Med Device Med Tech Med Device Med
Slide 6: Med Tech - Auryon
Med Tech - Auryon Combination of Auryon’s best-in-class technology and our commercial strategy have positioned Auryon as a consistently high-growth platform being supported by continued investment in use cases Period Sales YoY Growth Q1 2026 $16.5M 20.1% • Continued penetration into hospital setting
Slide 7: Med Tech – Thrombus Management
Med Tech – Thrombus Management Combination of AngioVac and AlphaVac represent a strong, highly competitive mechanical thrombectomy portfolio which continues to take market share driven by expanded joint commercial strategy Q1 2026 Sales YoY Growth AngioVac $8.0M 37.1% AlphaVac $3.3M 52.3% Total Mech
Slide 8: Med Tech - NanoKnife
Med Tech - NanoKnife Adoption has continued to accelerate within Prostate as this novel therapy gains traction following receipt of FDA clearance in Dec 2025 Q1 2026 Sales YoY Growth Disposables $5.4M 31.3% Capital $1.1M 8.0% Total $6.4M 26.7% • Accelerating demand for NanoKnife for prostate driving
Slide 9: Compelling FY 2026 Financial Outlook
Compelling FY 2026 Financial Outlook supported by balance sheet strength FY 2026 Net Sales ($M) FY 2026 Financial Guidance* $308 - $313 Current Metric Action Prior Guidance $293 Guidance Net Sales Increased $308 - $313M $305 - $310M +14 - 16% Med Tech Med Tech Net Sales Growth Increased +14 – 16% +1
Slide 10: Appendix
Appendix 10
Slide 11: Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements
Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements (in thousand, except per share data) 11
Slide 12: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and EPS
Reconciliation of GAAP Net Loss to Non- Reconciliation of Net Loss to Adjusted GAAP Adjusted Net Loss and EPS and Pro EBITDA and Pro Forma Adjusted EBITDA Forma Adjusted Net Loss and EPS (in thousands, except per share data) (in thousands, except per share data) 12
Slide 13: Detail of “Acquisition, Restructuring and Other Items, net”
Detail of “Acquisition, Restructuring and Other Items, net” 13
Slide 14: Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category
Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category (in thousands) 14